Targeting Hepatitis B Virus With CRISPR/Cas9

doi:10.1038/mtna.2014.68

PMC full text:

Mol Ther Nucleic Acids. 2014 Dec; 3(12): e216.

Published online 2014 Dec 16. doi: 10.1038/mtna.2014.68

Copyright/LicenseRequest permission to reuse: Copyright © 2014 American Society of Gene & Cell Therapy
This work is licensed under a Creative Commons Attribution 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/

<< PrevFigure 3Next >>

Figure 3

An external file that holds a picture, illustration, etc.
Object name is mtna201468f3.jpg

Inhibition of HBcAg expression with CRISPR/Cas9. (a) The results from an HBV infection on NTCP/cas9 cells expressing sg5 and sg7 guide RNAs. d, doxycycline. Immunofluorescence was performed with HBcAg-specific antibody C1-5 8 days after HBV infection. (b) Results from a quantitative analysis of HBcAg-positive cells from three different experiments performed with sgRNAs 5, 6, and 7, as described in a. Co, control; UI, uninfected. *P < 0.05; **P < 0.01; ***P < 0.001.

Figure 3

Images in this article

Click on the image to see a larger version.